SCHEMBL2440253

SCHEMBL2440253

CCOC(=O)CC(=O)Nc1cc(-c2nc3ccccc3nc2CC)n[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.48
PKM P14618 1/20 0.47
GAA P10253 1/20 0.40
MAPK8 P45983 1/20 0.40
MAPK9 P45984 1/20 0.40
MAPK10 P53779 1/20 0.40
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
KMT2A Q03164 2/20 0.38
HPGD P15428 2/20 0.38
MEN1 O00255 1/20 0.38
HSD17B10 Q99714 3/20 0.38
LMNA P02545 2/20 0.38
MAPT P10636 2/20 0.37
F2 P00734 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
PDE4B Q07343 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2436255 0.89 MAPK1 (0.50) MAPK1PKMMAPK8MAPK9MAPK10
SCHEMBL2440479 0.85 MAPK1 (0.48) MAPK1PKMGAAMAPK8MAPK9
SCHEMBL2436315 0.85 MAPK1 (0.46) MAPK1PKMGAAMAPK8MAPK9
SCHEMBL2439066 0.81 PKM (0.45) MAPK1PKMMAPK8MAPK9MAPK10
SCHEMBL2436439 0.80 PKM (0.46) MAPK1PKMGAAMAPK8MAPK9
SCHEMBL2435765 0.80 PKM (0.46) MAPK1PKMGAAMAPK8MAPK9
SCHEMBL2441561 0.80 PKM (0.47) MAPK1PKMGAAALDH1A1KDM4E
SCHEMBL2433967 0.79 MAPK1 (0.48) MAPK1PKMALDH1A1KDM4ESMN1; SMN2
SCHEMBL14120046 0.79 PKM (0.51) MAPK1PKMGAAALDH1A1KMT2A
SCHEMBL2439533 0.79 PKM (0.45) MAPK1PKMGAAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2539342-B1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2015-04-15 EP disclosed
US-8969376-B2 Pyrazolopyrimidine compounds and their use as PDE10 inhibitors MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-03-03 US disclosed
EP-2539342-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS Mitsubishi Tanabe Pharma Corporation (JP) 2013-01-02 EP disclosed
US-20120309754-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-12-06 US disclosed
WO-2011105628-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309754-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS PDE3B, PDE3A, PDE5A MAPK1 286/4885PKM 296/4885GAA 3618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.